Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Development of a dietary formulation of the SHetA2 chemoprevention drug for mice.

Benbrook DM, Janakiram NB, Chandra V, Pathuri G, Madka V, Stratton NC, Masamha CP, Farnsworth CN, Garcia-Contreras L, Hatipoglu MK, Lighfoot S, Rao CV.

Invest New Drugs. 2017 Dec 22. doi: 10.1007/s10637-017-0550-0. [Epub ahead of print]

PMID:
29273857
2.

Lack of chemopreventive effects of P2X7R inhibitors against pancreatic cancer.

Mohammed A, Janakiram NB, Madka V, Pathuri G, Li Q, Ritchie R, Biddick L, Kutche H, Zhang Y, Singh A, Gali H, Lightfoot S, Steele VE, Suen CS, Rao CV.

Oncotarget. 2017 Oct 26;8(58):97822-97834. doi: 10.18632/oncotarget.22085. eCollection 2017 Nov 17.

3.

Current Challenges and Opportunities for Chemoprevention of Pancreatic Cancer.

Mohammed A, Janakiram NB, Madka V, Li M, Asch AS, Rao CV.

Curr Med Chem. 2018;25(22):2535-2544. doi: 10.2174/0929867324666170209104453. Review.

PMID:
28183260
4.

Simultaneous targeting of 5-LOX-COX and ODC block NNK-induced lung adenoma progression to adenocarcinoma in A/J mice.

Kumar G, Patlolla JM, Madka V, Mohammed A, Li Q, Zhang Y, Biddick L, Singh A, Gillaspy A, Lightfoot S, Steele VE, Kopelovich L, Rao CV.

Am J Cancer Res. 2016 May 1;6(5):894-909. eCollection 2016.

5.

Small-Molecule Inhibition of GCNT3 Disrupts Mucin Biosynthesis and Malignant Cellular Behaviors in Pancreatic Cancer.

Rao CV, Janakiram NB, Madka V, Kumar G, Scott EJ, Pathuri G, Bryant T, Kutche H, Zhang Y, Biddick L, Gali H, Zhao YD, Lightfoot S, Mohammed A.

Cancer Res. 2016 Apr 1;76(7):1965-74. doi: 10.1158/0008-5472.CAN-15-2820. Epub 2016 Feb 15.

6.

Prevention and treatment of cancers by immune modulating nutrients.

Janakiram NB, Mohammed A, Madka V, Kumar G, Rao CV.

Mol Nutr Food Res. 2016 Jun;60(6):1275-94. doi: 10.1002/mnfr.201500884. Epub 2016 Mar 9. Review.

7.

TP53 modulating agent, CP-31398 enhances antitumor effects of ODC inhibitor in mouse model of urinary bladder transitional cell carcinoma.

Madka V, Mohammed A, Li Q, Zhang Y, Kumar G, Lightfoot S, Wu X, Steele V, Kopelovich L, Rao CV.

Am J Cancer Res. 2015 Sep 15;5(10):3030-41. eCollection 2015.

8.

Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo.

Madka V, Mohammed A, Li Q, Zhang Y, Biddick L, Patlolla JM, Lightfoot S, Towner RA, Wu XR, Steele VE, Kopelovich L, Rao CV.

Cancer Prev Res (Phila). 2016 Jan;9(1):53-62. doi: 10.1158/1940-6207.CAPR-15-0199. Epub 2015 Nov 17.

9.

Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma.

Rao CV, Janakiram NB, Madka V, Devarkonda V, Brewer M, Biddick L, Lightfoot S, Steele VE, Mohammed A.

Oncotarget. 2015 Oct 20;6(32):33290-305. doi: 10.18632/oncotarget.5396.

10.

Early and delayed intervention with rapamycin prevents NNK-induced lung adenocarcinoma in A/J mice.

Patlolla JM, Kopelovich L, Qian L, Zhang Y, Kumar G, Madka V, Mohammed A, Biddick L, Sadeghi M, Lightfoot S, Rao CV.

Oncol Rep. 2015 Dec;34(6):2925-34. doi: 10.3892/or.2015.4277. Epub 2015 Sep 16.

11.

Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression.

Mohammed A, Janakiram NB, Madka V, Brewer M, Ritchie RL, Lightfoot S, Kumar G, Sadeghi M, Patlolla JM, Yamada HY, Cruz-Monserrate Z, May R, Houchen CW, Steele VE, Rao CV.

Oncotarget. 2015 Jun 20;6(17):15524-39.

12.

Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling.

Mohammed A, Janakiram NB, Madka V, Ritchie RL, Brewer M, Biddick L, Patlolla JM, Sadeghi M, Lightfoot S, Steele VE, Rao CV.

Cancer Prev Res (Phila). 2014 Dec;7(12):1198-209. doi: 10.1158/1940-6207.CAPR-14-0176. Epub 2014 Sep 23.

13.

Evaluation of (99m)Tc-probestin SPECT as a novel technique for noninvasive imaging of kidney aminopeptidase N expression.

Pathuri G, Madka V, Hedrick AF, Lightfoot SA, Awasthi V, Cowley BD Jr, Rao CV, Gali H.

Mol Pharm. 2014 Aug 4;11(8):2948-53. doi: 10.1021/mp5002872. Epub 2014 Jul 10.

14.

Chemoprevention of urothelial cell carcinoma growth and invasion by the dual COX-LOX inhibitor licofelone in UPII-SV40T transgenic mice.

Madka V, Mohammed A, Li Q, Zhang Y, Patlolla JM, Biddick L, Lightfoot S, Wu XR, Steele V, Kopelovich L, Rao CV.

Cancer Prev Res (Phila). 2014 Jul;7(7):708-16. doi: 10.1158/1940-6207.CAPR-14-0087. Epub 2014 May 2.

15.

p53-stabilizing agent CP-31398 prevents growth and invasion of urothelial cancer of the bladder in transgenic UPII-SV40T mice.

Madka V, Zhang Y, Li Q, Mohammed A, Sindhwani P, Lightfoot S, Wu XR, Kopelovich L, Rao CV.

Neoplasia. 2013 Aug;15(8):966-74.

16.

Anti-inflammatory phytochemicals for chemoprevention of colon cancer.

Madka V, Rao CV.

Curr Cancer Drug Targets. 2013 Jun;13(5):542-57. Review.

PMID:
23597198
17.

Cancer stem cell markers as potential targets for epithelial cancers.

Madka V, Rao CV.

Indian J Exp Biol. 2011 Nov;49(11):826-35. Review.

PMID:
22126013
18.

The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model.

Mohammed A, Janakiram NB, Li Q, Madka V, Ely M, Lightfoot S, Crawford H, Steele VE, Rao CV.

Cancer Prev Res (Phila). 2010 Nov;3(11):1417-26. doi: 10.1158/1940-6207.CAPR-10-0038.

Supplemental Content

Support Center